Persistent neuroinflammation and neurodegeneration after brain injury
Abstract
ABSTRACT
INTRODUCTION: Traumatic brain injury (TBI) is a major global health issue in both civilians and war-affected military personnel and has no proper cure or treatment. Survivors of TBI exhibit long-term cognitive dysfunction and even permanent disabilities. As TBI patients exhibit multiple pathological conditions and the exact mechanism of neuroinflammation and neurodegeneration is still remain elusive. Therefore, we assess the prolonged effects of penetrating brain injury in animal model to further explore the neuroinflammation-associated neuropathological conditions in clinical studies.
OBJECTIVE: To determine the long term neuroinflammatory and neurodegenerative effects after penetrating brain injury in preclinical model.
METHODOLOGY: In the present study, we developed a penetrating brain injury and examined compare the neuroinflammatory effects after seven days and two months following brain injury in animal model. We used confocal laser microscopy to assess the expression of neuroinflammatory mediators in the mice group.
RESULTS: These findings provide evidence that penetrating brain injury have prolonged effects after two months. Using confocal laser microscopy, we found that the expression of GFAP (reactive astrocytes marker) and IL-1β (inflammatory marker) in the mice brain were significantly sustained after two months following brain injury, suggesting the prolonged neuroinflammatory effects after penetrating brain injury. Here, we found fascinating results that severity of neuroinflammation was higher at day 7 as compare to two months in animal brains.
CONCLUSION: These findings provide evidence that penetrating brain injury is critically involved in prolonged neuroinflammation which effect the cognitive ability and neurological impairments in the brain. Furthermore, these findings would be supportive in the preclinical and clinical settings.
KEY WORDS: inflammation, Traumatic brain injury, Astrocytes, interleukin beta.
References
Abrahamson, E.E., et al., Caspase inhibition therapy abolishes brain trauma-induced increases in Abeta peptide: implications for clinical outcome. Exp Neurol, 2006. 197(2): p. 437-50.
Karve, I.P., J.M. Taylor, and P.J. Crack, The contribution of astrocytes and microglia to traumatic brain injury. Br J Pharmacol, 2016. 173(4): p. 692-702.
DeKosky, S.T., M.D. Ikonomovic, and S. Gandy, Traumatic brain injury: football, warfare, and long-term effects. Minn Med, 2010. 93(12): p. 46-7.
Zihl, J. and O.F. Almeida, Neuropsychology of Neuroendocrine Dysregulation after Traumatic Brain Injury. J Clin Med, 2015. 4(5): p. 1051-62.
Muccigrosso, M.M., et al., Cognitive deficits develop 1month after diffuse brain injury and are exaggerated by microglia-associated reactivity to peripheral immune challenge. Brain Behav Immun, 2016. 54: p. 95-109.
Reifschneider, K., B.A. Auble, and S.R. Rose, Update of Endocrine Dysfunction following Pediatric Traumatic Brain Injury. J Clin Med, 2015. 4(8): p. 1536-60.
Lopez Rodriguez, A.B., et al., Estradiol decreases cortical reactive astrogliosis after brain injury by a mechanism involving cannabinoid receptors. Cereb Cortex, 2011. 21(9): p. 2046-55.
Andriessen, T.M., B. Jacobs, and P.E. Vos, Clinical characteristics and pathophysiological mechanisms of focal and diffuse traumatic brain injury. J Cell Mol Med, 2010. 14(10): p. 2381-92.
Morganti-Kossmann, M.C., et al., Modulation of immune response by head injury. Injury, 2007. 38(12): p. 1392-400.
Tsai, M.J., et al., Attenuating Spinal Cord Injury by Conditioned Medium from Bone Marrow Mesenchymal Stem Cells. J Clin Med, 2018. 8(1).
Kim, M.J., et al., Enhanced neuroprotection of anthocyanin-loaded PEG-gold nanoparticles against Abeta1-42-induced neuroinflammation and neurodegeneration via the NF-KB /JNK/GSK3beta signaling pathway. Nanomedicine, 2017. 13(8): p. 2533-2544.
Mazumder, M.K., et al., Neurological sequel of chronic kidney disease: From diminished Acetylcholinesterase activity to mitochondrial dysfunctions, oxidative stress and inflammation in mice brain. Sci Rep, 2019. 9(1): p. 3097.
Moreira, P.I., et al., Oxidative stress and neurodegeneration. Ann N Y Acad Sci, 2005. 1043: p. 545-52.
Cornelius, C., et al., Traumatic brain injury: oxidative stress and neuroprotection. Antioxid Redox Signal, 2013. 19(8): p. 836-53.
Li, D., et al., Regulation and role of ERK phosphorylation in glial cells following a nigrostriatal pathway injury. Brain Res, 2016. 1648(Pt A): p. 90-100.
Shlosberg, D., et al., Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol, 2010. 6(7): p. 393-403.
Campbell, M., et al., Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injury. Nat Commun, 2012. 3: p. 849.
Ransohoff, R.M. and M.A. Brown, Innate immunity in the central nervous system. J Clin Invest, 2012. 122(4): p. 1164-71.
Giunta, B., et al., The immunology of traumatic brain injury: a prime target for Alzheimer’s disease prevention. J Neuroinflammation, 2012. 9: p. 185.
Tajiri, N., et al., Suppressed cytokine expression immediatey following traumatic brain injury in neonatal rats indicates an expeditious endogenous anti-inflammatory response. Brain Res, 2014. 1559: p. 65-71.
Fluiter, K., et al., Inhibition of the membrane attack complex of the complement system reduces secondary neuroaxonal loss and promotes neurologic recovery after traumatic brain injury in mice. J Immunol, 2014. 192(5): p. 2339-48.
Bellander, B.M., et al., Complement activation in the human brain after traumatic head injury. J Neurotrauma, 2001. 18(12): p. 1295-311.
Sun, D., The potential of endogenous neurogenesis for brain repair and regeneration following traumatic brain injury. Neural Regen Res, 2014. 9(7): p. 688-92.
Mulherkar, S., et al., RhoA-ROCK Inhibition Reverses Synaptic Remodeling and Motor and Cognitive Deficits Caused by Traumatic Brain Injury. Sci Rep, 2017. 7(1): p. 10689.
Xiong, Y., A. Mahmood, and M. Chopp, Current understanding of neuroinflammation after traumatic brain injury and cell-based therapeutic opportunities. Chin J Traumatol, 2018. 21(3): p. 137-151.
